Rockefeller Capital Management L.P. trimmed its position in shares of Simulations Plus, Inc. (NASDAQ:SLP – Free Report) by 25.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 557,866 shares of the technology company’s stock after selling 188,092 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Simulations Plus were worth $10,170,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also bought and sold shares of SLP. Tudor Investment Corp ET AL bought a new stake in shares of Simulations Plus in the 3rd quarter worth about $1,810,000. Royce & Associates LP boosted its stake in shares of Simulations Plus by 31.6% during the 3rd quarter. Royce & Associates LP now owns 348,758 shares of the technology company’s stock worth $5,256,000 after purchasing an additional 83,758 shares during the period. Nicholas Company Inc. grew its holdings in Simulations Plus by 42.9% during the 4th quarter. Nicholas Company Inc. now owns 262,712 shares of the technology company’s stock valued at $4,789,000 after purchasing an additional 78,854 shares during the last quarter. JPMorgan Chase & Co. raised its position in Simulations Plus by 154.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 167,646 shares of the technology company’s stock worth $2,526,000 after purchasing an additional 101,822 shares during the period. Finally, First Light Asset Management LLC raised its position in Simulations Plus by 115.0% in the 3rd quarter. First Light Asset Management LLC now owns 767,760 shares of the technology company’s stock worth $11,570,000 after purchasing an additional 410,603 shares during the period. Institutional investors own 78.08% of the company’s stock.
Wall Street Analyst Weigh In
Several brokerages have issued reports on SLP. Craig Hallum lowered Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 target price for the company. in a research report on Thursday, June 18th. William Blair downgraded Simulations Plus from an “outperform” rating to a “market perform” rating in a report on Wednesday, June 17th. Weiss Ratings raised Simulations Plus from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, June 5th. Wall Street Zen lowered Simulations Plus from a “buy” rating to a “hold” rating in a research note on Saturday, June 13th. Finally, TD Cowen dropped their price objective on Simulations Plus from $19.00 to $16.00 and set a “hold” rating for the company in a report on Friday, April 10th. One research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Simulations Plus presently has an average rating of “Hold” and a consensus price target of $20.90.
Simulations Plus Price Performance
Shares of SLP opened at $18.16 on Thursday. Simulations Plus, Inc. has a 1-year low of $11.09 and a 1-year high of $21.01. The company has a 50-day moving average of $15.64 and a 200 day moving average of $15.55. The firm has a market capitalization of $366.93 million, a price-to-earnings ratio of -5.80 and a beta of 1.33.
Simulations Plus (NASDAQ:SLP – Get Free Report) last released its quarterly earnings data on Thursday, April 9th. The technology company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.08. The company had revenue of $24.29 million during the quarter, compared to analysts’ expectations of $21.66 million. Simulations Plus had a negative net margin of 77.96% and a positive return on equity of 16.21%. On average, equities analysts anticipate that Simulations Plus, Inc. will post 0.8 earnings per share for the current fiscal year.
Simulations Plus Profile
Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.
Featured Articles
- Five stocks we like better than Simulations Plus
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Want to see what other hedge funds are holding SLP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Simulations Plus, Inc. (NASDAQ:SLP – Free Report).
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.
